ALKBH5 and acute myeloid leukemia: We found that the percentage of METTL3‐, METTL14‐, WTAP‐, FTO‐, and ALKBH5‐positive primary AML cells was not significantly different from those in R/R‐AML (p > 0.05), with positive rates of 83.3% (20/24), 62.5% (15/24), 79.2% (19/24), 75% (18/24), and 58.3% (14/24), respectively.